Bebtelovimab Monoclonal Therapy EUA Guidance for COVID-19

ELIGIBILITY

Treatment of mild to moderate COVID-19 disease in patients:

- ✓ Positive SARS-COV 2 test
- ✓ Within **7 days** of symptom onset
- ✓ Age ≥ 12 years old
- ✓ Weight ≥ 40kg
- ✓ O2 sats ≥ 94% and not requiring increased supplemental oxygen in baseline rate due to COVID
- ✓ for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate

Have **ANY** of the following risk factors for progression to severe disease:

- ☐ BMI > 25 (or if age 12-17 BMI ≥ 85th percentile for age group)
- ☐ Chronic Kidney Disease
- ☐ Diabetes Mellitus
- ☐ Immunosuppressive disease or immunosuppressive treatment
- ☐ Age ≥ 65 years
- ☐ Cardiovascular disease
- ☐ Hypertension
- ☐ Pregnancy
- ☐ Sickle cell disease
- ☐ Congenital or acquired heart disease
- ☐ Medical related technological dependence (i.e. tracheostomy)
- ☐ Asthma, COPD, or other chronic respiratory disease

Bebtelovimab Health Care Provider Fact Sheet 03252022 (fda.gov)

DOSE

- ☐ Bebtelovimab 175mg as a single IV Push over at least 30 seconds
- ☐ Flush the injection line with 10 mL of 0.9% Sodium Chloride to ensure delivery of the entire dose

HOW TO ORDER

- ☐ Educate patient and obtain verbal consent
- ☐ Search in Epic under "**Monoclonal therapy**"
- ☐ **Choose the following panel:**
  Treatment of Mild-Moderate COVID-19
- ☐ The screening questions are built into the order set
- ☐ Send message to IC provider pool with patient name MRN (via telephone communication tool)
- ☐ The nurses will contact patient to schedule appointment
- ☐ Patient will be assessed upon arrival by urgent care provider and an order will be placed if patient is still meeting criteria